Vericel Corporation (VCEL) Stock Price

VCELStock
$43.22+14.23%52W
Market Cap$2.21B
P/E137.03x
PEG Ratio2.40
Div yield
Beta1.04

VCEL Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)1.83%
Price vs S&P 500 (4W)-12.49%
PEG Ratio2.40
VGM Score54.36
P/E Ratio (Annual)137.03x

VCEL Earnings Surprise History

Q2 25-0.01est. -0.04
Q3 250.10est. -0.01
Q4 250.45est. 0.38
Q1 26-0.12est. -0.16
Q2 260.04est. -0.03

VCEL Analyst Recommendations

May 2026
Jun 2026
Jul 2026
Aug 2026
4.21
4.21
4.21
4.21

Industry Peers — Biological Products(183)

SymbolValue ScoreGrowth ScoreMomentum ScorePrice
VCELVericel Corporation
DBC$43.22
AMGNAmgen IncCCB$442.24
GILDGilead Sciences IncCBB$148.77
MRNAModerna, Inc. Common StockDCA$158.83
ARGXargenx SE American Depositary SharesDAB$1019.49
RVMDRevolution Medicines, Inc. Common StockFA$211.38
BIIBBiogen Inc. Common StockCDB$220.77
BNTXBioNTech SE American Depositary ShareCCB$114.05
NBIXNeurocrine Biosciences IncCBC$153.37
EXELExelixis IncCBB$56.72
HALOHalozyme Therapeutics, Inc.CBA$109.32

About Vericel Corporation

Vericel is a biopharmaceutical company specializing in advanced cell therapies for sports medicine and severe burn care in the U.S. market. Its portfolio includes MACI (autologous cultured chondrocytes) for cartilage repair, Epicel (cultured epidermal autografts) for burn treatment, and NexoBrid. The company handles the full value chain from research and development through manufacturing and distribution.